MENQUADFI 55 MCG / 0.5 ML
TETANUS TOXOID : 55 MCG / 0.5 ML MENINGOCOCCAL GROUP Y POLYSACCHARIDE-TETANUS TOXOID CONJUGATE : 10 MCG / 0.5 ML MENINGOCOCCAL GROUP A POLYSACCHARIDE-TETANUS TOXOID CONJUGATE : 10 MCG / 0.5 ML MENINGOCOCCAL GROUP W POLYSACCHARIDE-TETANUS TOXOID CONJUGATE : 10 MCG / 0.5 ML MENINGOCOCCAL GROUP C POLYSACCHARIDE-TETANUS TOXOID CONJUGATE : 10 MCG / 0.5 ML · DIN 02507161 · SANOFI PASTEUR LIMITED
Health Canada status: MARKETED
What is MENQUADFI?
MENQUADFI 55 MCG / 0.5 ML contains TETANUS TOXOID : 55 MCG / 0.5 ML MENINGOCOCCAL GROUP Y POLYSACCHARIDE-TETANUS TOXOID CONJUGATE : 10 MCG / 0.5 ML MENINGOCOCCAL GROUP A POLYSACCHARIDE-TETANUS TOXOID CONJUGATE : 10 MCG / 0.5 ML MENINGOCOCCAL GROUP W POLYSACCHARIDE-TETANUS TOXOID CONJUGATE : 10 MCG / 0.5 ML MENINGOCOCCAL GROUP C POLYSACCHARIDE-TETANUS TOXOID CONJUGATE : 10 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02507161, held by SANOFI PASTEUR LIMITED, supplied as SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 01-Apr-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02507161 |
|---|---|
| Brand name | MENQUADFI |
| Generic / active ingredient | TETANUS TOXOID : 55 MCG / 0.5 ML MENINGOCOCCAL GROUP Y POLYSACCHARIDE-TETANUS TOXOID CONJUGATE : 10 MCG / 0.5 ML MENINGOCOCCAL GROUP A POLYSACCHARIDE-TETANUS TOXOID CONJUGATE : 10 MCG / 0.5 ML MENINGOCOCCAL GROUP W POLYSACCHARIDE-TETANUS TOXOID CONJUGATE : 10 MCG / 0.5 ML MENINGOCOCCAL GROUP C POLYSACCHARIDE-TETANUS TOXOID CONJUGATE : 10 MCG / 0.5 ML |
| Manufacturer | SANOFI PASTEUR LIMITED |
| Strength | 55 MCG / 0.5 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07AH08 MENINGOCOCCUS, A, C, Y, W-135, TETRAVAL. PURIFIED POLYSACC. ANTIGEN CONJUGATED |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Apr-2025 |
| Original market date | 2025-04-01 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code J07AH08 MENINGOCOCCUS, A, C, Y, W-135, TETRAVAL. PURIFIED POLYSACC. ANTIGEN CONJUGATED. 2 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MENVEO | 47 MCG / 0.5 ML | POWDER FOR SOLUTION ; SOLUTION | GLAXOSMITHKLINE INC | MARKETED | DIN 02347393 |
| MENACTRA | 4.0 MCG / 0.5 ML | SOLUTION | SANOFI PASTEUR LIMITED | CANCELLED POST MARKET | DIN 02279924 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.